ClinicalTrials.gg

Program

QLC7401

A development code. Also written as “QLC7401 Injection” and “QLC7401 injection”.

Its studies are mostly in Hyperlipoproteinemia Type II · Hypercholesterolemia, led by Qilu Pharmaceutical.

Furthest: phase 3, since Feb 11, 20265 company-led studies, 5 open or runningNext primary completion: Oct 7, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Qilu Pharmaceutical55 open or runningphase 3since Feb 11, 2026Dec 16, 2024Oct 7, 2027phase 3 · NCT07444086

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 16, 2024First study: phase 2 study in Hyperlipoproteinemia Type IIFirst studyNCT06750341 · 156 planned
  2. Jul 10, 2025Phase 1 study in Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-CNCT07074236 · 48 planned · China
  3. Feb 11, 20263 phase 3 studiesPhase 3 reachedNCT07441317, NCT07444086, NCT07450378

Ahead

  1. Oct 7, 2027Primary completion: phase 3 study in Hyperlipoproteinemia Type IINCT07444086
  2. Dec 2027Primary completion: phase 3 study in Hyperlipoproteinemia Type IINCT07441317
  3. Apr 2028Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07450378

TargetBeta

PCSK9 →read by rule
“QLC7401 is a small interfering RNA (siRNA) targeting PCSK9.”study text, by rule · the study

Other programs on PCSK9

ProgramCompanyFurthest phaseStudies
alirocumabruleSanofiphase 448
evolocumabruleAmgenphase 445
inclisiranruleNovartisphase 437
lerodalcibeprulelib-therapeutics-llcphase 314
tafolecimabruleInnovent Biologicsphase 38
recaticimabruleJiangsu HengRui Medicinephase 37
SAL003ruleShenzhen Salubris Pharmaceuticalsphase 33
VERVE-102Eli Lillyphase 22
DNV001rulehangzhou-dinovate-biotech-co-ltdphase 21
RBD7022ruleQilu Pharmaceuticalphase 12

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07450378Heterozygous Familial Hypercholesterolemia (HeFH)3Not yet recruitingApr 2028120
NCT07444086Hyperlipoproteinemia Type II3Not yet recruitingOct 7, 2027510
NCT07441317Hyperlipoproteinemia Type II3Not yet recruitingDec 2027780
NCT07074236Primary Hypercholesterolemia or Combined Hyperlipidemia Characterized by Elevated LDL-C · China1Not yet recruitingJan 202648
NCT06750341Hyperlipoproteinemia Type II2Not yet recruitingJun 2026156

How it is read

Names in the registry

  • “QLC7401”, 3 entries
  • “QLC7401 Injection”, 1 entry
  • “QLC7401 injection”, 1 entry

Codes read as this program: QLC7401.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.